30-årig tiltalt for at transportere svensk teenager til drabsmission Den danske medicinalgigant Novo Nordisk offentliggjorde i formiddag ... Aktien er i skrivende stund oppe med 8,99 procent, men kort ...

Den danske medicinalgigant Novo Nordisk er gået med til at sætte et ... døde 29. januar. Odense Kommune advarer nu børnehaver og institutioner mod den frygtede larve, der går under navnet ...

Vi bruger cookies for at gøre din oplevelse bedre. Enkelte bruges til reklameformål. Vi klatter ikke med dine data, og du kan altid trække dit samtykke tilbage. Læs mere her.

Ozempic er udviklet af den danske medicinalgigant Novo Nordisk. Det er et diabetesmiddel, men det medvirker også til vægttab. Novo Nordisk har fornyligt gjort sit indtog på Fyn med en megafabrik i ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...